Back to Search Start Over

Polymeric Nanoparticles: A Holistic Approach to Combat Tuberculosis.

Authors :
Rani S
Sharma AK
Kasu R
Gupta U
Source :
Critical reviews in therapeutic drug carrier systems [Crit Rev Ther Drug Carrier Syst] 2022; Vol. 39 (5), pp. 83-115.
Publication Year :
2022

Abstract

The emergence of multidrug-resistant (MDR) and extremely drug resistant (XDR) forms of pulmonary tuberculosis (TB) remains a major health challenge in this advanced era of health science. The longer therapy and higher dose of anti-tubercular drugs (ATDs) increases the patient incompliance at its peak levels of intolerance as well as toxicity. In the recent decades, nanoparticulate drug delivery has emerged as an excellent venture for the effective treatment of cancer, infectious diseases, brain as well as TB. Currently, encapsulation and conjugation of therapeutics to polymeric nanoparticles (PNPs) is an attractive strategy to enhance the effectivity of chemotherapeutics and minimize the toxic effects associated with ATDs. Various characteristics of nanoparticles (NPs) such as high stability, high loading efficiency, and high carrying capacity gives preference to the NPs over other drug delivery systems. Multiple or dual drug delivery concept is continuously gaining attention as a strict and favourable requirement of anti-TB therapy. The ideal properties of NPs including controlled or sustained drug release from the matrix enhances drug bioavailability with dose reduction and also enhance compliance of TB patients. Natural and synthetic polymers are playing important role in curtailing the side effects of chemotherapeutics. This review extensively highlights the drug delivery approaches of ATDs and emphasized on the importance and application of PNPs to combat TB.

Details

Language :
English
ISSN :
2162-660X
Volume :
39
Issue :
5
Database :
MEDLINE
Journal :
Critical reviews in therapeutic drug carrier systems
Publication Type :
Academic Journal
Accession number :
35993997
Full Text :
https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022039981